Your Destination for TCT 2024 Resources
Mechanical Circulatory Support of High-Risk PCI with a Novel, Low-Profile pMCS: First Results of the Impella ECP Pivotal Study
Amir Kaki, MD, presents on behalf of the Impella ECP Pivotal Study investigators at TCT 2024.
Join Abiomed at TCT 2024
Sessions of Interest
Sunday, Oct. 27
Impact of Microaxial Flow Pump on Central Hemodynamics and Use of Vasoactive Drugs During Intensive Care After Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial
Nanna Louise Junker Udesen, M.D., Ph.D. | Odense University Hospital
Microaxial Flow Pump Use and Renal Outcomes in Cardiogenic Shock: An Analysis of the DanGer Shock Trial
Jacob E. Møller, M.D., Ph.D., D.M.Sc | Odense University Hospital
Mechanical Circulatory Support of High-Risk PCI With a Novel, Low-Profile pMCS: First Results of the Impella ECP Pivotal Study
Amir Kaki, M.D. | St. John Ascension
Tuesday, Oct. 29
Results of DanGer Shock: Risks and Benefits of MCS for Cardiogenic Shock Put Into Perspective
Jacob E. Møller, M.D., Ph.D., D.M.Sc | Odense University Hospital
Ways in Which DanGer Will and Will Not Influence Clinical Practice in the US
David Morrow, M.D., MPH | BWH
Wednesday, Oct. 30
DanGer Shock: Impella Versus Standard Card for STEMI Patients with Cardiogenic Shock
Jacob E. Møller, M.D., Ph.D., D.M.Sc | Copenhagen/Odense, Denmark
DanGer Shock RCT
This independent investigator-initiated study is the first RCT of Impella in cardiogenic shock to complete enrollment. It assessed the efficacy of Impella CP® heart pumps in treating patients with AMICS shock due to STEMI, undergoing emergency PCI.
Review DanGer RCT Results
DanGer Shock Randomized Control Trial FAQs
This FAQ discusses the overall study significance, design and results.
Expand your femoral access skills using ultrasound guidance in a virtual environment.
Try Abiomed's New Virtual Reality Lab at Booth #2403
Protecting High-Risk PCI Patients
Identifying High-Risk PCI patients: Lessons from PROTECT III
See Our Latest Innovation
IMP-5852